RBD1016: EMA Grants Orphan Drug Designation for HDV Treatment
“`html
Ribo Pharmaceuticals Receives Orphan Drug Designation from EMA for HDV Treatment RBD1016
Table of Contents
Key Takeaways
Ribo Pharmaceuticals AB has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for its investigational siRNA therapeutic, RBD1016, designed to treat Hepatitis D Virus (HDV) infection. This designation accelerates advancement and potential commercialization of a much-needed therapy for a severe, often overlooked, liver disease. RBD1016 is currently in phase II clinical development, leveraging Ribo’s proprietary GalNAc-platform, RiboGalSTARTM.
Understanding the Breakthrough
on November 21, 2023, Ribo Pharmaceuticals announced that the EMA had granted Orphan Drug Designation to RBD1016. This designation is awarded to medicines intended for the diagnosis, prevention, or treatment of rare diseases affecting fewer than 5 in 10,000 people in the European Union. It provides various benefits, including market exclusivity, reduced regulatory fees, and scientific assistance from the EMA.
RBD1016 utilizes RNA interference (RNAi) technology, specifically small interfering RNA (siRNA), to selectively silence key viral factors essential for HDV infection. The drug candidate is delivered using Ribo’s GalNAc-platform, RiboGalSTARTM, designed for targeted delivery to the liver. Clinical trials are underway to assess the efficacy of RBD1016 in a global Phase II study.
the Significance of HDV and the Need for New Treatments
Hepatitis D Virus (HDV) is considered the most severe form of viral hepatitis, but it’s unique in that it requires the presence of Hepatitis B Virus (HBV) to replicate. The World Health Organization (WHO) estimates that approximately 12-20 million people worldwide are chronically infected with HDV. HDV accelerates liver disease progression, increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).
currently, treatment options for HDV are limited.Interferon alpha, the only approved therapy, has meaningful side effects and often results in low sustained virological response rates.This creates a substantial unmet medical need,making the development of therapies like RBD1016 critically significant.
| region | Estimated Cases |
|---|---|
| Asia | 8-12 million |
| Africa | 3-5 million |
| Europe | 1-2 million |
| Americas | 500,000 – 1 million |
Source: Based on data from WHO and published research (estimates vary).
Expert Viewpoint
“This designation is a significant regulatory milestone that enhances the